Avelumab antibody | AbD40519ia
A microtiter plate was coated overnight with various antigens at a concentration of 5 μg/ml. After washing and blocking with PBST + 5% BSA, detection was performed using HRP conjugated Human Anti-Avelumab Antibody, clone AbD40519ia (HCA396) at a concentration of 2 μg/ml in HISPEC Assay Diluent (BUF049A) followed by QuantaBlu Fluorogenic Peroxidase Substrate. HRP conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit (LNK002P).
A microtiter plate was coated overnight with avelumab, recombinant His-tagged human PD-L1, adalimumab, human IgG1 kappa control and human IgG1 lambda control at a concentration of 5 µg/ml. After washing and blocking with PBST + 5% BSA, detection was performed using HRP conjugated Human Anti-Avelumab Antibody, clone AbD40519ia (HCA396) titrated to the given concentrations in HISPEC Assay Diluent (BUF049A) followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements. HRP conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit (LNK002P).
A microtiter plate was coated overnight with recombinant His-tagged human PD-L1 at a concentration of 1 µg/ml. After washing and blocking with PBST + 5% BSA, a pre-incubated mixture of avelumab (0.15 µg/ml) plus increasing concentrations of Human Anti-Avelumab Antibody, clone AbD40519ia (HCA396) or Type 3 clone AbD42040ad (TZA042), both in the monovalent Fab format, were added. Free avelumab, still capable of binding to the human PD-L1 coated plate, was detected using HRP conjugated Mouse Anti-Human IgG (Fc) CH2 Domain Antibody (MCA647P) followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.
A microtiter plate was coated overnight with avelumab at a concentration of 1 µg/ml. After washing and blocking with PBST + 5% BSA, PBST with 10% human serum was added spiked with increasing concentrations of Human Anti-Avelumab Antibody, clone AbD40519ia (HCA396, black), clone AbD40525ia (HCA397, blue) or clone AbD40526ia (HCA398, red). Detection was performed using HRP conjugated avelumab at a concentration of 2 µg/ml in HISPEC Assay Diluent (BUF049A) followed by QuantaBlu Fluorogenic Peroxidase Substrate. HRP conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit (LNK002P). Data are shown as the mean of three measurements.
Human anti Avelumab
- Product Type
- Monoclonal Antibody
- Clone
- AbD40519ia
- Isotype
- IgG1
- Specificity
- Avelumab
Antibody Quality and Performance Guarantee
HCA396
| Human Anti-Avelumab Antibody, clone AbD40519ia is a paratope specific, inhibitory anti-idiotypic antibody (Type 1) that specifically recognizes the free human monoclonal antibody drug avelumab. The antibody does not recognize free PD-L1 nor avelumab in complex with PD-L1. This antibody can be used to measure free avelumab levels in serum from patients. This antibody is available in three formats: as a full length IgG1 antibody (HCA396) for use in ADA assays, as well as two formats incorporating a SpyTag: a monovalent recombinant Fab format (TZA040), and a bivalent SpyTag Fab format (TZA040P) coupled with a HRP conjugated BiSpyCatcher2 (TZC002P).Either Fab format can be used to develop a pharmacokinetic (PK) bridging ELISA to measure free avelumab captured via immobilized PD-L1. Avelumab (Bavencio) is a human IgG1/lambda antibody with allotype IGHG1*05 (G1m17,1). It binds to programmed death-ligand 1 (PD-L1, CD274) on tumor cells, blocking its interaction with PD-1 and B7-1 receptors on T-lymphocytes. PD-L1 is an immune checkpoint protein expressed on tumor cells and tumor-infiltrating immune cells that down regulates T-cell function, so by blocking these receptors anti-tumor T-cell activity can be restored. In vitro, the drug has been shown to stimulate natural killer cell-mediated direct tumor cell lysis by inducing antibody-dependent cell-mediated cytotoxicity. Avelumab has been approved both as monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC) and for the treatment of advanced Renal Cell Carcinoma (RCC). |
|
- Product Form
- Human IgG1 antibody (lambda light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Source
- HKB-11
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
- Immunogen
- Avelumab
- Affinity
- The monovalent intrinsic affinity of Human anti-Avelumab Antibody, clone AbD40519ia was measured as KD = 0.9 nM by real time, label-free molecular interaction analysis on immobilized avelumab.
- Approx. Protein Concentrations
- Antibody concentration 0.5 mg/ml
- Regulatory
- For research purposes only
- Guarantee
- 12 months from date of despatch
- Acknowledgements
- This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details.
Bavencio is a registered trademark of Merck Serono (Pfizer as co-developer). - Licensed Use
- For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA |  |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual.
- ELISA
- This product may be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera together with HCA397 and HCA398.
Protocol: ADA bridging ELISA
| Description | Product Code | Applications | Pack Size | List Price | Your Price | Quantity | |
|---|---|---|---|---|---|---|---|
| Hispec Assay Diluent | BUF049A | E IY | 50 ml | Log in | |||
| List Price | Your Price | ||||||
| Log in | |||||||
| Description | Hispec Assay Diluent | ||||||
| Human anti Avelumab | HCA397 | E | 0.1 mg |
|
Log in | ||
| List Price | Your Price | ||||||
|
|
Log in | ||||||
| Description | Human anti Avelumab | ||||||
| Human anti Avelumab | HCA398 | E | 0.1 mg |
|
Log in | ||
| List Price | Your Price | ||||||
|
|
Log in | ||||||
| Description | Human anti Avelumab | ||||||
| LYNX Rapid HRP Antibody Conjugation Kit | LNK002P | CJ | 3 Conjugations For 400µg Antibody | Log in | |||
| List Price | Your Price | ||||||
| Log in | |||||||
| Description | LYNX Rapid HRP Antibody Conjugation Kit | ||||||
| Human anti Avelumab | TZA040 | E | 0.1 mg | Log in | |||
| List Price | Your Price | ||||||
| Log in | |||||||
| Description | Human anti Avelumab | ||||||
| Human anti Avelumab:HRP | TZA040P | E | 0.1 mg | Log in | |||
| List Price | Your Price | ||||||
| Log in | |||||||
| Description | Human anti Avelumab:HRP | ||||||
| Human anti Avelumab | TZA041 | E | 0.1 mg | Log in | |||
| List Price | Your Price | ||||||
| Log in | |||||||
| Description | Human anti Avelumab | ||||||
| Human anti Avelumab (Drug/Target Complex) | TZA042 | E | 0.1 mg | Log in | |||
| List Price | Your Price | ||||||
| Log in | |||||||
| Description | Human anti Avelumab (Drug/Target Complex) | ||||||
| Human anti Avelumab (Drug/Target Complex):HRP | TZA042P | E | 0.1 mg | Log in | |||
| List Price | Your Price | ||||||
| Log in | |||||||
| Description | Human anti Avelumab (Drug/Target Complex):HRP | ||||||
- Synonyms
- Bavencio
HCA396
167377
If you cannot find the batch/lot you are looking for please contact our technical support team for assistance.
View more products with Avelumab specificity
Please Note: All Products are "FOR RESEARCH PURPOSES ONLY"
Always be the first to know.
When we launch new products and resources to help you achieve more in the lab.
Yes, sign me up